[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mcd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mcd":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,99,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100591638","phase-2-atacicept-in-multiple-glomerular-diseases-100591638",false,"NCT06983028","Atacicept in Multiple Glomerular Diseases","A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)","Inclusion Criteria:\n\n* Weight of at least 40 kg\n* On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease\n* Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.\n\nDiagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome\n\nFor patients enrolling in IgAN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy proven IgAN, IgAVN, or recurrent IgAN in kidney transplant\n* UPCR ≥ 0.5 g\u002Fg or UPE ≥ 0.5 g\u002Fday on 24h urine\n* eGFR≥ 20 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pediatric IgAN Cohorts (eligibility varies by cohort):\n\n* Age ≥ 2 years and \\\u003C 18 years\n* Biopsy proven IgAN or IgAVN\n* On stable prescribed regimen of RAASi (or SoC) for at least 8 weeks\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* eGFR≥ 30 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pMN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy-proven pMN\n* Anti PLA2R antibodies ≥ 25 RU\u002FmL\n* UPCR ≥ 1.5 g\u002Fg or UPE ≥ 1.5 g\u002Fd on 24h urine\n* At low risk for spontaneous remission (based on severity or duration of disease)\n\nFor patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):\n\n* Age ≥ 10 years\n* eGFR ≥30 mL\u002Fmin\u002F1.73m2\n* Adults with biopsy diagnosis of primary MCD or FSGS (adults) or children with challenging clinical course with steroids (frequenlty relapsing, steroid-dependent, or steroid-resistant)\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* Evidence of anti-nephrin antibodies\n\nKey Exclusion Criteria:\n\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)\n* Active viral or bacterial infections\n* Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study\n* Administration of live and live-attenuated vaccinations within 30 days prior to enrollment\n* Immunosuppressant medications within 4 weeks prior to dosing with atacicept (except transplant maintenance immunosuppression).\n* Known hypersensitivity to atacicept or any component of the formulated atacicept\n* Additional criteria apply to each cohort\u002Fdisease.","ALL","2 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.",[26,27,28,29,30],"pMN","IgAN","Nephrotic Syndrome","MCD","FSGS",[32,33,34,35,36,37,28,38,39,40,41,42,43,44,45,46,47],"IGA Glomerulonephritis","IGA Nephropathy","Iga Nephropathy 1","Immunoglobulin A Nephropathy Nephritis","IGA Type Nephropathy, IGA","Primary Membranous Nephropathy","Immunoglobulin A (IgA)","Immunoglobulin A vasculitis with nephritis (IgAVN)","Anti-PLA2R associated membranous nephropathy (PLA2R-MN)","Idiopathic\u002Fprimary nephrotic syndrome (MCD\u002FFSGS)","Glomerulonephritis","Nephritis","Autoimmune Diseases","Immune System Diseases","Kidney Diseases","Glomerulonephritis, IGA","RECRUITING","2026-06-23",{"date":51,"type":52},"2026-06-26","ACTUAL",{"date":54,"type":52},"2025-07-07",{"date":56,"type":20},"2027-11",{"name":58,"class":59},"Vera Therapeutics, Inc.","INDUSTRY",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":84,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100406380","neptune-match-study-100406380","NCT04571658","NEPTUNE Match Study","Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)","NEPTUNE Match","Inclusion Criteria:\n\n1. Consented and eligible participants in the biopsied or non-biopsied cohorts of the NEPTUNE observational study\n2. Must be potentially eligible for the NEPTUNE Match partnering trials (e.g. if no trial is enrolling a participant under age 6, those under 6 are not eligible).\n\n   Note: NEPTUNE Match partnering trials and associated eligibility criteria are expected to be dynamic and change as trial protocols are developed, activated, and amended.\n3. Regular nephrology healthcare provided at a NEPTUNE study site.\n4. Willing and able to consent, and as appropriate assent, to participate in NEPTUNE Match\n\nExclusion Criteria:\n\nCurrently non-NEPTUNE observational study participants are not eligible to be matched to a clinical trial using these biomarker assessments.\n\nExclusion Criteria:\n\n1\\. Non-English or non-Spanish speaking","1 Year","80 Years",{"count":72,"type":20},375,[74],"NA","NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.",[77,78,79,80,81,30,29,82,83],"Nephrotic Syndrome in Children","Focal Segmental Glomerulosclerosis","Minimal Change Disease","Minimal Change Nephrotic Syndrome","Membranous Nephropathy","MCD - Minimal Change Disease","Alport Syndrome",[28,85,86,87],"NEPTUNE","Match","Clinical Trial Match","2026-06-08",{"date":90,"type":52},"2026-06-10",{"date":92,"type":52},"2022-05-02",{"date":94,"type":20},"2029-12-30",{"name":96,"class":97},"University of Michigan","OTHER",16,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":60},"100613471","phase-1-a-study-to-evaluate-the-safety-tolerability-and-pk-of-sk-09-100613471","NCT07267026","A Study to Evaluate the Safety, Tolerability and PK of SK-09","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of SK-09 in Healthy Adult Participants","Inclusion Criteria:\n\n1. Healthy male and female participants aged 18 to 55 years (inclusive) at the time of screening.\n2. Weight and BMI for female and male participants:\n\n   Body weight ≥ 50 kg; Body mass index (BMI) between 18.5 and 29.9 kg\u002Fm2 (inclusive)\n3. Participants must be in good general health.\n4. Capable of understanding and voluntarily providing written informed consent prior to any study-related procedures.\n5. Participants must have no plans for conception during the trial and for 3 months after the last dose, and must voluntarily use effective contraception with no plans for sperm or egg donation .\n\nExclusion Criteria:\n\n1. History or current presence of clinically significant Cardiovascular; Respiratory ; Gastrointestinal; Neurological ; Hematologic\u002Fimmunologic disorders.\n2. Chronic GI conditions requiring daily medication; or history of bariatric surgery.\n3. Live\u002Fattenuated vaccines within 4 weeks prior to dosing or planned during study.\n4. Systolic blood pressure \\\u003C 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure ≥80 mmHg.\n5. History of myocardial infarction, angina, coronary artery bypass grafting, angioplasty, stenting, congestive heart failure, uncontrolled hypotension, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms\u002Ffamily history of QT prolongation syndrome, as assessed by the investigator to be unsuitable for participation.\n6. Positive results for hepatitis B surface antigen, syphilis-specific antibodies, hepatitis C antibodies, or HIV antibodies.\n7. Major surgery or trauma requiring hospitalization within 6 months.\n8. Hypersensitivity to any component of SK-09 or its excipients.\n9. Poor venous access or needle phobia impacting study procedures.\n10. History of alcohol abuse or binge drinking and\u002For any other illicit drug use or dependence within 6 months.\n11. Current smokers unwilling to abstain during study.\n12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening and confirmed by a single repeat test, if deemed necessary:\n\n    * AST or ALT level ≥ 1.5×ULN;\n    * Total bilirubin level ≥ 1.5×ULN (except Gilbert's with direct bilirubin ≤ ULN)\n13. Blood loss or donation exceeding 400 mL within 3 months of dosing.\n14. Other investigational product within 30 days of dosing or 5 half-lives (whichever longer).\n15. Use of any medications, including over-the-counter drugs, herbal medicine, vitamins, and health supplements, within 2 weeks prior to the first dose or 5 half-lives (whichever longer).\n16. Positive pregnancy test or breastfeeding.\n17. Unprotected sexual activity within 2 weeks prior to the first dose.\n18. Any condition that, in the investigator's opinion, may pose a safety risk to the participant, interfere with the study, or prevent the participant from completing the study or complying with its requirements (due to administrative or other reasons).\n19. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",true,"18 Years","55 Years",{"count":110,"type":20},72,[112],"PHASE1","This Phase 1 trial consists of two parts: Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design.",[30,29],"2026-06-04",{"date":117,"type":52},"2026-06-05",{"date":119,"type":52},"2025-12-08",{"date":121,"type":20},"2026-10-04",{"name":123,"class":59},"Consun Pharmaceutical Group",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":60},"100489246","recurrence-post-transplant-observational-study-in-focal-segmental-glomerulosclerosis-and-minimal-change-disease-100489246","NCT05650619","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)","RESOLVE","Inclusion Criteria:\n\n* Retrospective non-consented participant group had a transplant from the year 2000 and onward.\n* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).\n\nExclusion Criteria:\n\n* Pathologic diagnosis other than FSGS or MCD\n* FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)",{"count":133,"type":20},300,"OBSERVATIONAL","The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes.\n\nThe purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.",[78,79,30,29],[138,139,140,141,142],"Kidney disease","Kidney transplant","Adult","Children","Recurrence","2026-04-23",{"date":145,"type":52},"2026-04-29",{"date":147,"type":52},"2022-12-08",{"date":149,"type":20},"2027-12",{"name":96,"class":97}]